Prot #FGCL-3019-091: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

Project: Research project

Project Details

StatusFinished
Effective start/end date9/9/19 → 6/30/25

Funding

  • Worldwide Clinical Trials, Inc. ((OE) Prot #FGCL-3019-091 // (OE) Prot #FGCL-3019-091)
  • FibroGen, Inc. ((OE) Prot #FGCL-3019-091 // (OE) Prot #FGCL-3019-091)